<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kwak EA</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of General Medical Sciences</funding><funding>NIDA NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1326</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8921520</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>Defective angiogenesis underlies over 50 malignant, ischemic and inflammatory disorders yet long-term therapeutic applications inevitably fail, thus highlighting the need for greater understanding of the vast crosstalk and compensatory mechanisms. Based on proteomic profiling of angiogenic endothelial components, here we report β&lt;sub>IV&lt;/sub>-spectrin, a non-erythrocytic cytoskeletal protein, as a critical regulator of sprouting angiogenesis. Early loss of endothelial-specific β&lt;sub>IV&lt;/sub>-spectrin promotes embryonic lethality in mice due to hypervascularization and hemorrhagic defects whereas neonatal depletion yields higher vascular density and tip cell populations in developing retina. During sprouting, β&lt;sub>IV&lt;/sub>-spectrin expresses in stalk cells to inhibit their tip cell potenti</pubmed_abstract><journal>Nature communications</journal><pubmed_title>β&lt;sub>IV&lt;/sub>-spectrin as a stalk cell-intrinsic regulator of VEGF signaling.</pubmed_title><pmcid>PMC8921520</pmcid><funding_grant_id>P30 DA051355</funding_grant_id><funding_grant_id>GM128055</funding_grant_id><funding_grant_id>P30 CA023074</funding_grant_id><funding_grant_id>R01 CA219495</funding_grant_id><funding_grant_id>R01 GM128055</funding_grant_id><pubmed_authors>Lee YS</pubmed_authors><pubmed_authors>Largent-Milnes T</pubmed_authors><pubmed_authors>Ahmed T</pubmed_authors><pubmed_authors>Cruz-Flores P</pubmed_authors><pubmed_authors>Vanderah TW</pubmed_authors><pubmed_authors>Langlais PR</pubmed_authors><pubmed_authors>Mohler PJ</pubmed_authors><pubmed_authors>Kwak EA</pubmed_authors><pubmed_authors>Ramonett A</pubmed_authors><pubmed_authors>Lochhead JJ</pubmed_authors><pubmed_authors>Pan CC</pubmed_authors><pubmed_authors>Kumar S</pubmed_authors><pubmed_authors>Hund TJ</pubmed_authors><pubmed_authors>Lee NY</pubmed_authors><pubmed_authors>Mouneimne G</pubmed_authors><pubmed_authors>Mythreye K</pubmed_authors><pubmed_authors>Georgieva TG</pubmed_authors><pubmed_authors>Ortiz HR</pubmed_authors><pubmed_authors>Ellis NA</pubmed_authors></additional><is_claimable>false</is_claimable><name>β&lt;sub>IV&lt;/sub>-spectrin as a stalk cell-intrinsic regulator of VEGF signaling.</name><description>Defective angiogenesis underlies over 50 malignant, ischemic and inflammatory disorders yet long-term therapeutic applications inevitably fail, thus highlighting the need for greater understanding of the vast crosstalk and compensatory mechanisms. Based on proteomic profiling of angiogenic endothelial components, here we report β&lt;sub>IV&lt;/sub>-spectrin, a non-erythrocytic cytoskeletal protein, as a critical regulator of sprouting angiogenesis. Early loss of endothelial-specific β&lt;sub>IV&lt;/sub>-spectrin promotes embryonic lethality in mice due to hypervascularization and hemorrhagic defects whereas neonatal depletion yields higher vascular density and tip cell populations in developing retina. During sprouting, β&lt;sub>IV&lt;/sub>-spectrin expresses in stalk cells to inhibit their tip cell potenti</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-04T13:18:34.097Z</modification><creation>2025-04-04T13:18:34.097Z</creation></dates><accession>S-EPMC8921520</accession><cross_references><pubmed>35288568</pubmed><doi>10.1038/s41467-022-28933-1</doi></cross_references></HashMap>